OTCMKTS:IPIX

Innovation Pharmaceuticals Stock Forecast, Price & News

$0.19

0.00 (0.00 %)

(As of 05/14/2021 12:00 AM ET)

Add

Compare

Today's Range

$0.18

▼

$0.20

50-Day Range

$0.18

▼

$0.28

52-Week Range

$0.13

▼

$0.65

Volume705,298 shs

Average Volume2.17 million shs

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive IPIX News and Ratings via Email

Sign-up to receive the latest news and ratings for Innovation Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Innovation Pharmaceuticals

Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. It develops Brilacidin, a lead drug compound for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company also develops Kevetrin, a lead anti-cancer compound for treating ovarian cancer. It has license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.

Innovation Pharma Surpasses 50 Percent Enrollment in Phase 2 Clinical Trial of Brilacidin for COVID-19
April 28, 2021 | finance.yahoo.com

Innovation Pharmaceuticals (OTCMKTS:IPIX) Trading Down 3.3%
April 28, 2021 | americanbankingnews.com

Innovation Pharma's Broad Spectrum Antiviral Drug Candidate Brilacidin Highlighted in Biodefense and Infectious Diseases COVID-19 Presentation
April 14, 2021 | marketwatch.com

Innovation Pharma’s Broad Spectrum Antiviral Drug Candidate Brilacidin Highlighted in Biodefense and Infectious Diseases COVID-19 Presentation
April 14, 2021 | finance.yahoo.com

Innovation Pharma Announces Brilacidin Abstract Accepted for Oral Presentation at the American Society for Virology’s Annual Meeting
April 7, 2021 | finance.yahoo.com

Innovation Pharma Completes Interim Safety Data Review—DMC Approves Increased Dosing Frequency in Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients
April 5, 2021 | finance.yahoo.com

Recruitment and Enrollment Underway at Eight Sites for Innovation Pharma’s Phase 2 Clinical Trial of Brilacidin for COVID-19
March 5, 2021 | finance.yahoo.com

Innovation Pharmaceuticals Announces Publication of Peer-Reviewed Scientific Article in the Journal Viruses on the Anti-SARS-CoV-2 Properties of Brilacidin
March 2, 2021 | finance.yahoo.com

Innovation Pharma Provides Study Details for Ongoing Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients
February 26, 2021 | finance.yahoo.com

Innovation Pharmaceuticals’ Phase 2 Clinical Trial of Brilacidin for Treating COVID-19 Scheduled to Begin Next Week
January 29, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:IPIX

Previous Symbol

CUSIPN/A

CIK1355250

Webwww.cellceutix.com

Phone(978) 236-8717

Employees4

Year FoundedN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Miscellaneous

Outstanding SharesN/A

Market CapN/A

Next Earnings DateN/A

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.56 out of 5 stars

Medical Sector

1458th out of 2,044 stocks

Biotechnology Industry

76th out of 158 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Innovation Pharmaceuticals.

2.8 Community Rank

Outperform Votes
Innovation Pharmaceuticals has received 55 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Innovation Pharmaceuticals has received 44 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Innovation Pharmaceuticals has received 55.56% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Innovation Pharmaceuticals and other stocks. Vote “Outperform” if you believe IPIX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IPIX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Innovation Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Innovation Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Innovation Pharmaceuticals insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Innovation Pharmaceuticals (OTCMKTS:IPIX) Frequently Asked Questions

What stocks does MarketBeat like better than Innovation Pharmaceuticals?

Wall Street analysts have given Innovation Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Innovation Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Innovation Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Innovation Pharmaceuticals' stock was trading at $0.1250 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IPIX stock has increased by 49.3% and is now trading at $0.1866.
View which stocks have been most impacted by COVID-19.

Who are Innovation Pharmaceuticals' key executives?

Innovation Pharmaceuticals' management team includes the following people:

Mr. Leo Ehrlich, Chairman, CEO, CFO, Principal Accounting Officer & Sec. (Age 63, Pay $465.85k)
Ms. Jane Harness, Sr. VP of Clinical Sciences & Portfolio Management (Age 53, Pay $365.75k)
Dr. W. James Alexander, Consultant (Age 71)
Mr. Jim Boeheim, Bus. Advisor

Who are some of Innovation Pharmaceuticals' key competitors?

Some companies that are related to Innovation Pharmaceuticals include (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), 17031 (MYM), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), ADiTx Therapeutics (ADTX), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF) and Almirall (LBTSF).
View all of IPIX's competitors.

What other stocks do shareholders of Innovation Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innovation Pharmaceuticals investors own include Vaxart (VXRT), Broadcom (AVGO), Fulcrum Therapeutics (FULC), VIVUS (VVUS), CytoDyn (CYDY), ServiceNow (NOW), Sorrento Therapeutics (SRNE), United Airlines (UAL), Heat Biologics (HTBX) and Micron Technology (MU).

What is Innovation Pharmaceuticals' stock symbol?

Innovation Pharmaceuticals trades on the OTCMKTS under the ticker symbol "IPIX."

How do I buy shares of Innovation Pharmaceuticals?

Shares of IPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Innovation Pharmaceuticals' stock price today?

One share of IPIX stock can currently be purchased for approximately $0.19.

How many employees does Innovation Pharmaceuticals have?

Innovation Pharmaceuticals employs 4 workers across the globe.

What is Innovation Pharmaceuticals' official website?

The official website for Innovation Pharmaceuticals is www.cellceutix.com.

Where are Innovation Pharmaceuticals' headquarters?

Innovation Pharmaceuticals is headquartered at 100 Cummings Ctr Ste 151b, BEVERLY, MA 01915-6117, United States.

How can I contact Innovation Pharmaceuticals?

Innovation Pharmaceuticals' mailing address is 100 Cummings Ctr Ste 151b, BEVERLY, MA 01915-6117, United States. The company can be reached via phone at (978) 236-8717.

This page was last updated on 5/15/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Innovation Pharmaceuticals Stock Forecast, Price & News

Adding

Adding

Adding Innovation Pharmaceuticals Inc.

About Innovation Pharmaceuticals

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

Consensus Rating

2.8 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment